DelveInsight’s “Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Glioblastoma Multiforme, historical and forecasted epidemiology as well as the Glioblastoma Multiforme market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Glioblastoma Multiforme, offering comprehensive insights into the Glioblastoma Multiforme revenue trends, prevalence, and treatment landscape. The report delves into key Glioblastoma Multiforme statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Glioblastoma Multiforme therapies. Additionally, we cover the landscape of Glioblastoma Multiforme clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Glioblastoma Multiforme treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Glioblastoma Multiforme space.

To Know in detail about the Glioblastoma Multiforme market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Glioblastoma Multiforme Market Forecast

Some of the key facts of the Glioblastoma Multiforme Market Report: 

• The Glioblastoma Multiforme market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• Key Glioblastoma Multiforme Companies: Genentech, Merck, VBL Therapeutics, Diffusion Pharmaceuticals, Karyopharm Therapeutics, Immunomic Therapeutics, Medicenna Therapeutics, Inc., TVAX Biomedical, BPGbio, Precision Life Sciences Group, MedImmune LLC, Oryx GmbH & Co. KG, Acerta Pharma BV, Myrexis Inc., Tracon Pharmaceuticals Inc., Rigshospitalet, Exelixis, and others

• Key Glioblastoma Multiforme Therapies: Avastin, Temodar/Temodal, Ofranergene obadenovec (VB-111), Trans Sodium Crocetinate, Selinexor (KPT-330), VBI-1901: VBI VaccinesITI-1000 (pp65 DC Vaccine), MDNA55, TVI-Brain-1, Erlotinib HCl (OSI-774), BPM31510, ICT-107, MEDI-575, H-1PV, ACP-196, Azixa, TRC105, Temsirolimus, XL184, and others

• The Glioblastoma Multiforme market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glioblastoma Multiforme pipeline products will significantly revolutionize the Glioblastoma Multiforme market dynamics.

• In November 2023, BioMimetix revealed promising results from its Phase II trial of BMX-001, a leading candidate for treating high-grade glioma, at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting. The trial showed that BMX-001, when used with radiotherapy and temozolomide, led to a 6.6-month increase in median survival, reduced radiation-induced cognitive problems, and enhanced white matter integrity, all while maintaining a tolerable safety profile compared to the current standard of care.

• In 2023, the US reported the highest number of new cases among the 7MM, totaling approximately 13,600.

• In 2023, Germany reported the highest number of new cases among the EU4 and the UK, with France following.

• In the US, there were about 12,200 cases of Primary GBM/IDH-wild Type and 1,360 cases of Secondary GBM/IDH Mutant among the type-specific incident cases.

• In the US, the incident cases classified histologically included approximately 13,200 cases of Glioblastoma Multiforme, 110 cases of giant cell Glioblastoma Multiforme, and 270 cases of gliosarcoma.

Glioblastoma Multiforme Overview

Glioblastoma Multiforme is a highly aggressive and malignant brain tumor that originates from glial cells, which support and protect nerve cells. It is characterized by rapid growth and infiltrative behavior, making it challenging to treat. Glioblastoma Multiformes often present with symptoms such as headaches, seizures, and neurological deficits, and they typically require a combination of surgery, radiation therapy, and chemotherapy for management. Despite treatment, Glioblastoma Multiformes have a high recurrence rate and a generally poor prognosis.

Get a Free sample for the Glioblastoma Multiforme Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market

Glioblastoma Multiforme Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Glioblastoma Multiforme Epidemiology Segmentation:

The Glioblastoma Multiforme market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Incident Cases of GBM in the 7MM

• Age-specific Incident Cases of GBM in the 7MM

• Gender-specific Incident Cases of GBM in the 7MM

• Incident Cases based on Primary Site of GBM in the 7MM

• Type-specific Incident Cases of GBM in the 7MM

• Incident Cases based on Histologic Classification of GBM in the 7MM

Download the report to understand which factors are driving Glioblastoma Multiforme epidemiology trends @ Glioblastoma Multiforme Epidemiology Forecast

Glioblastoma Multiforme Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glioblastoma Multiforme market or expected to get launched during the study period. The analysis covers Glioblastoma Multiforme market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Glioblastoma Multiforme Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Glioblastoma Multiforme Therapies and Key Companies

• Avastin: Genentech

• Temodar/Temodal: Merck

• Ofranergene obadenovec (VB-111): VBL Therapeutics

• Trans Sodium Crocetinate: Diffusion Pharmaceuticals

• Selinexor (KPT-330): Karyopharm Therapeutics

• VBI-1901: VBI VaccinesITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics

• MDNA55: Medicenna Therapeutics, Inc.

• TVI-Brain-1: TVAX Biomedical

• Erlotinib HCl (OSI-774): Genentech, Inc.

• BPM31510: BPGbio

• ICT-107: Precision Life Sciences Group

• MEDI-575: MedImmune LLC

• H-1PV: Oryx GmbH & Co. KG

• ACP-196: Acerta Pharma BV

• Azixa: Myrexis Inc.

• TRC105: Tracon Pharmaceuticals Inc.

• Temsirolimus: Rigshospitalet

• XL184: Exelixis

Discover more about therapies set to grab major Glioblastoma Multiforme market share @ Glioblastoma Multiforme Treatment Landscape

Glioblastoma Multiforme Market Strengths

• Vaccine approaches are an attractive adjuvant therapy for solid tumors because they can generate long-term immune surveillance against cancer cells. MimiVax (SurVaxM), Immunomic Therapeutics (ITI-1000), and IMVAX (IGV-001) are some of the key players developing therapeutic vaccines for GBM.

• Nanocarrier delivery has emerged as a promising approach, especially for drug transport across the blood–brain barrier (BBB) using methods such as nanoparticles or prodrugs.

Glioblastoma Multiforme Market Opportunities

• The GBM market is currently using temozolomide and bevacizumab as approved therapies, but the market lacks an effective strategy to cure GBM, which provides a lucrative opportunity to develop more treatment options.

• Conditional and time-limited approval of Daiichi’s Delytact, an intratumoral oncolytic virus therapy, has opened new doors for other players such as DNAtrix and Istari Oncology to develop oncolytic virus therapies, which can prove to be a potential mechanism of action in brain cancer treatment in future.

Scope of the Glioblastoma Multiforme Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Glioblastoma Multiforme Companies: Genentech, Merck, VBL Therapeutics, Diffusion Pharmaceuticals, Karyopharm Therapeutics, Immunomic Therapeutics, Medicenna Therapeutics, Inc., TVAX Biomedical, BPGbio, Precision Life Sciences Group, MedImmune LLC, Oryx GmbH & Co. KG, Acerta Pharma BV, Myrexis Inc., Tracon Pharmaceuticals Inc., Rigshospitalet, Exelixis, and others

• Key Glioblastoma Multiforme Therapies: Avastin, Temodar/Temodal, Ofranergene obadenovec (VB-111), Trans Sodium Crocetinate, Selinexor (KPT-330), VBI-1901: VBI VaccinesITI-1000 (pp65 DC Vaccine), MDNA55, TVI-Brain-1, Erlotinib HCl (OSI-774), BPM31510, ICT-107, MEDI-575, H-1PV, ACP-196, Azixa, TRC105, Temsirolimus, XL184, and others

• Glioblastoma Multiforme Therapeutic Assessment: Glioblastoma Multiforme current marketed and Glioblastoma Multiforme emerging therapies

• Glioblastoma Multiforme Market Dynamics: Glioblastoma Multiforme market drivers and Glioblastoma Multiforme market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Glioblastoma Multiforme Unmet Needs, KOL’s views, Analyst’s views, Glioblastoma Multiforme Market Access and Reimbursement 

To know more about Glioblastoma Multiforme companies working in the treatment market, visit @ Glioblastoma Multiforme Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Glioblastoma Multiforme Market Report Introduction

2. Executive Summary for Glioblastoma Multiforme

3. SWOT analysis of Glioblastoma Multiforme

4. Glioblastoma Multiforme Patient Share (%) Overview at a Glance

5. Glioblastoma Multiforme Market Overview at a Glance

6. Glioblastoma Multiforme Disease Background and Overview

7. Glioblastoma Multiforme Epidemiology and Patient Population

8. Country-Specific Patient Population of Glioblastoma Multiforme 

9. Glioblastoma Multiforme Current Treatment and Medical Practices

10. Glioblastoma Multiforme Unmet Needs

11. Glioblastoma Multiforme Emerging Therapies

12. Glioblastoma Multiforme Market Outlook

13. Country-Wise Glioblastoma Multiforme Market Analysis (2019–2032)

14. Glioblastoma Multiforme Market Access and Reimbursement of Therapies

15. Glioblastoma Multiforme Market Drivers

16. Glioblastoma Multiforme Market Barriers

17.  Glioblastoma Multiforme Appendix

18. Glioblastoma Multiforme Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:27 Drydock Ave S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services